Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset
neurodegenerative disorder. In 2007, a novel locus, SAX2, which is located on
chromosome 17p13 and contains 3 genes, ankyrin repeat and FYVE domain-containing 1
(ANKFY1), β-arrestin 2 (ARRB2) and
kinesin family member 1C (KIF1C), was linked to ARSACS. We generated
Ankfy1 heterozygous (Ankfy1/+) mice to establish an animal model and examine the
pathophysiological basis of ARSACS. The transgenic mice displayed an abnormal gait
with progressive motor and cerebellar nerve dysfunction that was highly reminiscent
of ARSACS. These clinical features were accompanied by an early-onset and progressive
loss of Purkinje cells, followed by gliosis. Additionally, the loss of Ankfy1
function resulted in an abnormal expression of neurotrophic factors (NTFs) in the
Ankfy1/+ mouse cerebellum. Moreover, Purkinje cells cultured from neonatal Ankfy1/+
mice exhibited a shorter dendritic length and decreased numbers of dendritic spines.
Importantly, cerebellar Purkinje cells from Ankfy1/+ mice and cells transfected with
a lentiviral Ankfy1 shRNA underwent apoptosis. We propose that transgenic Ankfy1/+
mice are a useful model for studying the pathogenesis of ARSACS and for exploring the
molecular mechanisms involved in this neurodegenerative disease.